FDA fast tracks ADHD drug centanafadine, targeting approval by July 24 for treatment across all age groups, based on phase 3 trial results.

The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

The agency is currently reviewing the study findings ...

News and commentary from the psychiatry world ...

A commonly used ADHD medication is being recalled nationwide after failing lab tests. The medication, lisdexamfetamine dimesylate capsules, is the generic form of Vyvanse, a stimulant that improves ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the U.S. Food and Drug Administration (FDA) has accepted for priority ...

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.

A large multicenter clinical trial led by King's College London with 150 children and adolescents has shown that a device cleared by the US FDA to treat ADHD is not effective in reducing symptoms. The ...

A large multicenter clinical trial led by King's College London with 150 children and adolescents has shown that a device cleared by the US FDA to treat ADHD is not effective in reducing symptoms. The ...

Kenvue, the American company that makes Tylenol, says the U.S. Food and Drug Administration should not make proposed changes to the product’s safety label to reflect research about a possible ...